Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2049)
All Articles published online
|
Nov 14, 2006 (publication date) through Nov 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C. World J Gastroenterol 2006; 12(42): 6786-6791 [PMID: 17106926 DOI: 10.3748/wjg.v12.i42.6786] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i42/6786.htm |
| Number | Citing Articles |
| 1 |
Hamid Namazi. ACE Inhibitors: A Novel Treatment for Neurofibroma. Annals of Surgical Oncology 2008; 15(5): 1538 doi: 10.1245/s10434-007-9737-5
|
| 2 |
Hala M. Raslan, Khalda S. Amr, Yasser A. Elhosary, Wafaa M. Ezzat, Nour A. Abdullah, Hassan E. El-Batae. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection. Transactions of the Royal Society of Tropical Medicine and Hygiene 2011; 105(7): 396 doi: 10.1016/j.trstmh.2011.03.005
|
| 3 |
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic options. Clinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
|
| 4 |
Puneeta Tandon, Juan G. Abraldes, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Jaime Bosch. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. Journal of Hepatology 2010; 53(2): 273 doi: 10.1016/j.jhep.2010.03.013
|
| 5 |
Montserrat Moreno, Ramon Bataller. Cytokines and Renin-Angiotensin System Signaling in Hepatic Fibrosis. Clinics in Liver Disease 2008; 12(4): 825 doi: 10.1016/j.cld.2008.07.013
|
| 6 |
Hamid Namazi. Effect of intraurethral captopril gel on the recurrence of urethral stricture after direct vision internal urethrotomy: A novel molecular mechanism. International Journal of Urology 2008; 15(6): 562 doi: 10.1111/j.1442-2042.2008.02072.x
|
| 7 |
J. Macías, M. M. Viloria, A. Rivero, I. Santos, M. Márquez, J. Portilla, F. Di Lello, A. Camacho, J. Sanz-Sanz, G. Ojeda, R. Mata, J. Gómez-Mateos, J. A. Pineda. Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. European Journal of Clinical Microbiology & Infectious Diseases 2012; 31(8): 2083 doi: 10.1007/s10096-012-1546-5
|
| 8 |
Yavuz Beyazit, Mehmet İbis, Tugrul Purnak, Turan Turhan, Murat Kekilli, Mevlut Kurt, Abdurrahim Sayilir, İbrahim Koral Onal, Nesrin Turhan, Adnan Tas, Seyfettin Köklü, İbrahim C. Haznedaroglu. Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal Sclerosis. Digestive Diseases and Sciences 2011; 56(7): 2160 doi: 10.1007/s10620-011-1580-7
|
| 9 |
Amanda M Murphy, Alison L Wong, Michael Bezuhly. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis & Tissue Repair 2015; 8(1) doi: 10.1186/s13069-015-0023-z
|
| 10 |
|
| 11 |
Kathleen E. Corey, Nirali Shah, Joseph Misdraji, Barham K. Abu Dayyeh, Hui Zheng, Atul K. Bhan, Raymond T. Chung. The effect of angiotensin‐blocking agents on liver fibrosis in patients with hepatitis C. Liver International 2009; 29(5): 748 doi: 10.1111/j.1478-3231.2009.01973.x
|
| 12 |
Qianqian Zhu, Na Li, Fang Li, Zhihua Zhou, Qunying Han, Yi Lv, Jiao Sang, Zhengwen Liu. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosis. Journal of the Renin-Angiotensin-Aldosterone System 2016; 17(1) doi: 10.1177/1470320316628717
|
| 13 |
Pablo Muriel, Yadira Rivera‐Espinoza. Beneficial drugs for liver diseases. Journal of Applied Toxicology 2008; 28(2): 93 doi: 10.1002/jat.1310
|
| 14 |
Fiona J. Warner, Harinda Rajapaksha, Nicholas Shackel, Chandana B. Herath. ACE2: from protection of liver disease to propagation of COVID-19. Clinical Science 2020; 134(23): 3137 doi: 10.1042/CS20201268
|
| 15 |
Alessandro Siani. Pharmacological Treatment of Fibrosis: a Systematic Review of Clinical Trials. SN Comprehensive Clinical Medicine 2020; 2(5): 531 doi: 10.1007/s42399-020-00292-2
|
| 16 |
Yue-Cheng Guo, Lun-Gen Lu. Antihepatic Fibrosis Drugs in Clinical Trials. Journal of Clinical and Translational Hepatology 2020; 8(4): 1 doi: 10.14218/JCTH.2020.00023
|
| 17 |
Zuo-Wei Ning, Xiao-Ying Luo, Guo-Zhen Wang, Yang Li, Miao-Xia Pan, Ren-Qiang Yang, Xu-Guang Ling, Shan Huang, Xiao-Xin Ma, Si-Yi Jin, Dan Wang, Xu Li. MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1. Antioxidants & Redox Signaling 2017; 27(1): 1 doi: 10.1089/ars.2016.6669
|